International Clinical Trial: Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117016) titled 'Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer' on Jan. 19.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shengjing Hospital of China Medical University

Condition: Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer

Intervention: Experimental Group:Trilaciclib: 240 mg/m2, administered as a 30-minute intravenous infusion completed within 4 hours prior to chemotherapy. Sintilimab: 200 mg, administered every 3 weeks (Q3W). Pemetr...